N
enVVeno Medical Corp
NVNOCIK 0001661053NasdaqNon-AcceleratedSmaller ReportingSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-19.47M
Total Assets
$29.56M
Equity
$27.13M
Shares Out
655.5K
Op. Cash Flow
$-15.57M
Business
enVVeno Medical Corp is a late clinical-stage medical device company focused on developing bioprosthetic, tissue-based solutions to treat venous disease, particularly severe chronic venous insufficiency of the deep venous system. It offers surgical and transcatheter replacement venous valves, primarily the VenoValve surgical implant and the enVVe non-surgical transcatheter valve. Key activities include clinical development, pre-clinical testing, regulatory submissions, and in-house manufacturing of Class III tissue-based implantable devices. The company targets the U.S. market initially and conducts distribution and clinical studies through hospitals, surgical centers and interventional cardiology/vascular channels.
Summary from filing dated 2025-02-28
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development expenses | 10 | 12 | 14 | 10 | 6 | |
| Selling, general and administrative expenses | 11 | 12 | 12 | 15 | 11 | |
| Loss from operations | −21 | −24 | −25 | −25 | −17 | |
| Realized gain from sales of trading securities | 1 | 2 | 1 | 53,000 | — | |
| Unrealized loss from trading securities | −400,000 | −22,000 | 468,000 | 49,000 | — | |
| Interest income | 692,000 | 389,000 | 180,000 | 161,000 | — | |
| Total other income | 1 | 2 | 2 | 263,000 | −365,000 | |
| Net loss | −19 | −22 | −24 | −25 | −17 | |
| Net loss per basic common share | −33.06 | −44.53 | −1.91 | −2.2 | −1.9 | |
| Net loss per diluted common share | −33.06 | −44.53 | −1.91 | −2.2 | — | |
| Basic | 589,000 | 490,000 | 12 | 11 | 9 | |
| Diluted | 589,000 | 490,000 | 12 | 11 | — |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 2 | 4 | 5 | 55 | |
| Short-term investments | 25 | 41 | 43 | 34 | — | |
| Prepaid expenses and other current assets | 614,000 | 581,000 | 511,000 | 392,000 | 312,000 | |
| Total current assets | 29 | 44 | 47 | 39 | 55 | |
| Property and equipment, net | 51,000 | 182,000 | 334,000 | 521,000 | 618,000 | |
| Operating lease right-of-use assets, net | 654,000 | 1 | 1 | 2 | 2 | |
| Security deposits and other assets | 31,000 | 31,000 | 31,000 | 31,000 | 54,000 | |
| Total assets | 30 | 45 | 49 | 42 | 58 | |
| Accounts payable, accrued expenses and other current liabilities | 2 | 2 | — | 568,000 | 729,000 | |
| Current portion of operating lease liabilities | 390,000 | 364,000 | 338,000 | 314,000 | 291,000 | |
| Total current liabilities | 2 | 2 | 1 | 2 | 2 | |
| Long-term operating lease liabilities | 310,000 | 700,000 | 1 | 1 | 2 | |
| Total liabilities | 2 | 3 | 2 | 3 | 3 | |
| Commitments and Contingencies Note 10 | — | — | — | — | — | |
| Preferred stock, par value $0.00001, 10,000 shares authorized: no shares issued or outstanding | — | — | — | — | — | |
| Common stock, par value $0.00001, 250,000 shares authorized, 656 and 501 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — | — | — | — | |
| Additional paid-in capital | 198 | 194 | 176 | 145 | 136 | |
| Accumulated deficit | −171 | −152 | −130 | −107 | −82 | |
| Total stockholders equity | 27 | 42 | 46 | 39 | 54 | |
| Total liabilities and stockholders equity | 30 | 45 | 49 | 42 | 58 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 4 | 5 | 9 | 6 | |
| Depreciation and amortization | 136,000 | 189,000 | 220,000 | 212,000 | 149,000 | |
| Amortization of right-of-use assets | 353,000 | 339,000 | 326,000 | 313,000 | 304,000 | |
| Prepaid expenses and other current assets | −33,000 | −70,000 | −119,000 | −80,000 | −38,000 | |
| Accounts payable, accrued expenses and other current liabilities | 1,000 | 698,000 | −183,000 | — | — | |
| Operating lease liabilities | −364,000 | −338,000 | −314,000 | −290,000 | −313,000 | |
| Net cash used in operating activities | −16 | −17 | −19 | −16 | −12 | |
| Maturities of investments | 62 | 57 | 49 | 14 | — | |
| Purchase of investments | −46 | −56 | −57 | −48 | — | |
| Purchases of property and equipment | −5,000 | −37,000 | −33,000 | −115,000 | −368,000 | |
| Net cash provided by investing activities | 16 | 1 | −8 | −35 | −368,000 | |
| Proceeds from the sale of common stock and pre-funded warrants in public offering, net of fees | — | 14 | — | — | — | |
| Proceeds from sale of common stock in At-the-Market offering, net of fees | 782,000 | — | — | — | — | |
| Proceeds from exercise of warrants | 241,000 | — | — | — | 245,000 | |
| Proceeds from exercise of stock options | — | 46,000 | — | — | — | |
| Net cash provided by financing activities | 1 | 14 | 26 | — | 58 | |
| Net increase (decrease) in cash and cash equivalents | 1 | −2 | −935,000 | −50 | 45 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro